” Federal health advisers said that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance. But as with their review of a similar drug a day earlier, the Food and Drug Administration experts stressed Wednesday that long-term results are needed to judge the drug’s real benefit.

Click here to read original article